Trial reportBone marrow transplantation2008
Randomized phase III study of granulocyte transfusions in neutropenic patients.
Trial report in Bone marrow transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction.The Cochrane database of systematic reviews · 2016Pooled it
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction.The Cochrane database of systematic reviews · 2015Pooled it
- Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Annals of hematology · 2014Guideline
- Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia.PloS one · 2016Trial
- Trial
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study.Transfusion · 2025Article
- Human induced pluripotent stem cells derived neutrophils display strong anti-microbial potencies.Cell regeneration (London, England) · 2025Article
- Granulocyte Transfusions in Neutropenic Infections: Insights From a Single-Center Study.Cureus · 2024Article
- Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.Mycopathologia · 2023Review
- A randomized controlled trial to explore the safety and efficacy of irradiated buffy-coat granulocytes in pediatric patients with febrile neutropenia.American journal of blood research · 2023Article
- Natural Killer Cell Line NK-92-Mediated Damage of Medically Important Fungi.Journal of fungi (Basel, Switzerland) · 2021Article
- Immune-Based Anti-Staphylococcal Therapeutic Approaches.Microorganisms · 2021Review
- Genetic Vaccination as a Flexible Tool to Overcome the Immunological Complexity of Invasive Fungal Infections.Frontiers in microbiology · 2021Review
- In canine bacterial pneumonia circulating granulocyte counts determine outcome from donor cells.Transfusion · 2020Article
- The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions.Transfusion · 2019Article
- Immunomodulation as a Therapy forJournal of fungi (Basel, Switzerland) · 2018Review
- An International Registry of Granulocyte Transfusions.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2018Review
- Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives.Oncotarget · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite antibiotics, antifungals and haematopoietic growth factors, infections remain a major threat to neutropenic patients. To determine the role of granulocyte transfusions (GTs) in anti-infective therapy during neutropenia, GT administration was randomized in 74 adults with haematological or malignant diseases, febrile neutropenia and pulmonary or soft-tissue infiltrates after conventional or high-dose chemotherapy, a majority of them after allo-SCT (n=39). Neutrophil reconstitution was equal in the treatment and control arm. GT toxicity was minimal. The probability of 28-day survival after randomization was >80% in both groups, and no effect of GT on survival until day 100 could be detected in patients with fungal (n=55), bacterial or unknown infection (n=17) and various levels of neutropenia (ANC <500 vs >500 x 10(6)/l). These findings can be attributed primarily to procedural obstacles, such as long delay from randomization to first GT, low cell content and slow sequence of GT, difficulties in randomizing a safe and potentially life-saving treatment in severely endangered individuals, and a large proportion of rapidly recovering patients in both arms. The requirement of another trial in a more specific patient population with daily transfusions of sufficient numbers of granulocytes to support or refute the empirically acknowledged benefits of GT is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.